Last 5 Days Trading Activity
|Date||Open Price||Close Price||High||Low||Volume|
Last 5 Days Short Activity
|Date||Short Volume||Total Volume||Short Percentage||Short Indicator|
* Short Mode
About Agennix AG (OTC: GAGXF)
Agennix AG is a publicly listed biopharmaceutical company that is focused on the development of novel therapies that have the potential to substantially improve the length and quality of life of critically ill patients in areas of major unmet medical need. The Company s most advanced program is talactoferrin, an oral immunotherapy that has demonstrated activity in randomized, double blind, placebo controlled Phase II studies in non small cell lung cancer and in severe sepsis. Talactoferrin is currently in Phase III clinical trials in non small cell lung cancer, and a Phase II/III trial with talactoferrin in severe sepsis is underway. Other clinical development programs include RGB , a multi targeted kinase inhibitor in Phase I testing, and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix s registered seat is in Heidelberg, Germany. The Company has three sites of operation: Planegg/Munich, Germany Princeton, New Jersey and Houston, Texas.
- Torsten Hombeck / CFO
- Rajesh Malik / CMO
Current Share Structure
- Market Cap: $9,218,000 - 03/19/2018
- Issue and Outstanding: 41,900,000 - 07/31/2011
Daily Technical Chart for (OTC: GAGXF)
Stay tuned for daily updates and more on (OTC: GAGXF)
More to come on (OTC: GAGXF)
Do your DD and if you choose, be ready to go!
The Research: All source information contained in this email is from the public sources mentioned below.
Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GAGXF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of GAGXF and does not buy, sell, or trade any shares of GAGXF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/